"Alector stock drops after Alzheimer’s drug fails in Phase II trial" was originally created and published by Clinical Trials ...

Alector’s AbbVie-partnered Alzheimer's asset has failed to slow disease progression in a phase 2 study, the latest in a ...

Alector is kicking off a resource realignment effort that will include a workforce reduction of around 17%. The biotech ...

Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on Alector (ALEC – Research Report), reducing the price target to $7.00.Don't ...

The brain drug developer is letting go of around 41 of its 238 employees, in a move the company says will help “align ...

Alector Therapeutics, working with AbbVie, was testing whether modulating immune cells in brain would slow Alzheimer's ...

Alector's AL002 fails in Phase 2 Alzheimer's trial, halting extension study; focus shifts to other programs as workforce is ...

BTIG analyst Thomas Shrader maintained a Buy rating on Alector (ALEC – Research Report) yesterday and set a price target of $5.00. Don't Miss our Black Friday Offers: Unlock your investing potential ...

Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for ...

Alector Therapeutics said that its Phase 2 trial for an experimental Alzheimer’s antibody failed, dealing a blow to what had ...

On Monday, Alector Inc (ALEC) stock saw a modest uptick, ending the day at $3.96 which represents a slight increase of $0.02 or 0.51% from the prior close of $3.94. The stock opened at $4.01 and ...

Investigational simufilam failed to reduce cognitive or functional decline in Alzheimer's disease patients in the ReThink-ALZ ...